Search results for "statin"

showing 10 items of 545 documents

Non lipid, dose-dependent effects of pravastatin treatment on hemostatic system and inflammatory response

2000

Objectives: The aim of the present study was to evaluate the effects of pravastatin treatment on lipid, inflammation, and coagulation parameters in patients suffering from myocardial infarction with or without carotid atherosclerotic lesions (groups 1 and 2, respectively). Methods: In the first phase of the study, a cross-sectional comparison of lipid, inflammation, and coagulation parameters was performed between the patients and the control group (group 3). Highly significant differences in these parameters were observed, especially in group 1. In the second phase of the study, we assessed the effects of a persistent reduction in cholesterol synthesis induced by increasing doses of pravas…

Blood GlucoseMalemedicine.medical_specialtyMyocardial InfarctionInflammationCoronary Artery DiseaseFibrinogenchemistry.chemical_compoundRisk FactorsInternal medicinemedicineHumansPharmacology (medical)PravastatinInflammationPharmacologyDose-Response Relationship DrugFactor VIIbusiness.industryCholesterolpravastatin inflammatory responseGeneral MedicineMiddle AgedBlood Coagulation FactorsCholesterolCross-Sectional StudiesEndocrinologyCoagulationchemistryCase-Control StudiesHemostasisFemalelipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase Inhibitorsmedicine.symptombusinessPravastatinmedicine.drugLipoproteinEuropean Journal of Clinical Pharmacology
researchProduct

Therapeutic tools for oral candidiasis : current and new antifungal drugs

2019

Background Candidiasis is one of the most common opportunistic oral infections that presents different acute and chronic clinical presentations with diverse diagnostic and therapeutic approaches. The present study carries out a bibliographic review on the therapeutic tools available against oral candidiasis and their usefulness in each clinical situation. Material and Methods Recent studies on treatment of oral candidiasis were retrieved from PubMed and Cochrane Library. Results Nystatin and miconazole are the most commonly used topical antifungal drugs. Both antifungal drugs are very effective but need a long time of use to eradicate the infection. The pharmacological presentations of mico…

AzolesNystatinmedicine.medical_specialtyAntifungal AgentsDatabases FactualMiconazolePyridinesItraconazoleAdministration TopicalAdministration OralReviewAnidulafunginEchinocandins03 medical and health scienceschemistry.chemical_compound0302 clinical medicineCandidiasis OralCaspofunginAmphotericin BNitrilesmedicineHumansDrug InteractionsClotrimazoleFluconazoleGeneral DentistryVoriconazoleOral Medicine and Pathologybusiness.industryClotrimazole030206 dentistryTriazoles:CIENCIAS MÉDICAS [UNESCO]bacterial infections and mycosesDermatologyNystatinOtorhinolaryngologychemistryUNESCO::CIENCIAS MÉDICASAnidulafunginAdministration IntravenousSurgeryCaspofunginMiconazolebusinessFluconazolemedicine.drug
researchProduct

Analysis and modulation of the inflammatory response through lung agression related to bacterial infection and mechanical ventilation

2015

Despite major advances since decades in the management of ventilated patients, ventilator-associated pneumonia (VAP) continues to complicate the course of approximately 28% of the patients receiving mechanical ventilation (MV). Among patients hospitalized in intensive care units, the risk of pneumonia is 3- to 10- fold increased in MV patients. However, MV is often the only way to care for critically ill patients with respiratory failure. It has now been clearly demonstrated that MV, in particular adverse ventilatory strategies could activate lung cells, thus leading to a proinflammatory response, even in the absence of pathogen. This is the biotrauma paradigm, which accounts, at least in p…

InflammationVentilation mécaniqueLésions pulmonairesStatinsPneumonie acquise sous ventilation mécaniquePneumonia[SDV.BC]Life Sciences [q-bio]/Cellular BiologyLung injuryStatinesProne positionMechanical ventilationDécubitus ventralAlarminesPneumonieAlarminsVentilator-associated pneumoniaInfection[SDV.BC] Life Sciences [q-bio]/Cellular Biology
researchProduct

The efficacy and safety of ezetimibe/simvastatin combination compared with intensified lipid-lowering treatment strategies in diabetic subjects with …

2012

Aims The objective was to assess the consistency of effect of switching to ezetimibe/simvastatin 10/20 mg versus doubling the baseline statin dose (to simvastatin 40 mg or atorvastatin 20 mg) or switching to rosuvastatin 10 mg across subgroups of subjects with (n = 617) and without (n = 191) metabolic syndrome (MetS). Methods This was a post hoc analysis of a randomized, double-blind, 6-week study of adults 18–79 years with cardiovascular disease and diabetes mellitus with low-density lipoprotein cholesterol (LDL-C) ≥70 and ≤160 mg/dl. The percent change in LDL-C and other lipids was estimated within each subgroup separately. Safety and tolerability were assessed. Results In subjects with M…

Blood GlucoseMaleSimvastatinEndocrinology Diabetes and MetabolismAtorvastatinEzetimibe Simvastatin Drug CombinationPharmacologyEndocrinologyAtorvastatinMedicineRosuvastatin CalciumMetabolic SyndromeSulfonamidesAnticholesteremic AgentsFastingMiddle AgedDrug CombinationsTreatment OutcomeTolerabilityCardiovascular Diseaseslipids (amino acids peptides and proteins)Drug Therapy CombinationFemalemedicine.drugAdultmedicine.medical_specialtyStatinAdolescentmedicine.drug_classUrologyDrug Administration ScheduleEzetimibeDouble-Blind MethodDiabetes mellitusInternal MedicineHumansRosuvastatinPyrrolescardiovascular diseasesAgedApolipoproteins Bbusiness.industrynutritional and metabolic diseasesCholesterol LDLmedicine.diseaseFluorobenzenesDiabetes Mellitus Type 1PyrimidinesDiabetes Mellitus Type 2SimvastatinHeptanoic AcidsAzetidinesMetabolic syndromebusinessDiabetic AngiopathiesDiabetes, obesitymetabolism
researchProduct

The clinical relevance of low-density-lipoproteins size modulation by statins.

2006

The predominance of small, dense low density lipoproteins (LDL) has been accepted as an emerging cardiovascular risk factor by the National Cholesterol Education Program Adult Treatment Panel III; in fact, LDL size seems to be an important predictor of cardiovascular events and progression of coronary heart disease. Several studies have also shown that the therapeutical modulation of LDL size is of great benefit in reducing the risk of cardiovascular events. Hypolipidemic treatment is able to alter LDL subclass distribution and statins are currently the most widely used lipid-lowering agents. Statins are potent inhibitors of hydroxy-methyl-glutaryl-coenzyme A reductase, the rate-limiting en…

Simvastatinmedicine.medical_specialtyIndolesStatinmedicine.drug_classAtorvastatinFatty Acids MonounsaturatedInternal medicineAtorvastatinmedicineHumansPyrrolesPharmacology (medical)RosuvastatinParticle SizeRosuvastatin CalciumFluvastatinNational Cholesterol Education ProgramPharmacologySulfonamidesVascular diseasebusiness.industryAnticholesteremic Agentsstatins small dense LDL coronary heart disease atherosclerosis prevention therapyGeneral Medicinemedicine.diseaseFluorobenzenesLipoproteins LDLPyrimidinesEndocrinologyCardiovascular DiseasesHeptanoic AcidsSimvastatinlipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessPravastatinmedicine.drugFluvastatin
researchProduct

Mevolonate Pathway:role of bisphosphonates and statins

2006

Cardiovascular diseases, i.e. high blood pressure, coronary heart disease, and stroke, and osteoporosis are public health problems, with several epidemiological links, and they might be related to each other in terms of pathogenesis and therapeutic agents. Bisphosphonates inhibit bone resorption and are used in the treatment of osteoporosis, whereas statins inhibit cholesterol biosynthesis and are used for the treatment of atherosclerosis and lipid metabolic disorders. Some late clinical studies suggested bisphosphonates may have beneficial effect in vivo on atherosclerotic progression, lipid profiles, and cardiovascular morbidity and mortality, whereas statins might increase bone density, …

Bisphosphonates statins atherosclerosis osteoporosis
researchProduct

Association of statin use and clinical outcomes in heart failure patients : a systematic review and meta-analysis

2019

Abstract Background The role of statins in patients with heart failure (HF) of different levels of left ventricular ejection fraction (LVEF) remains unclear especially in the light of the absence of prospective data from randomized controlled trials (RCTs) in non-ischemic HF, and taking into account potential statins’ prosarcopenic effects. We assessed the association of statin use with clinical outcomes in patients with HF. Methods We searched PubMed, EMBASE, Scopus, Google Scholar and Cochrane Central until August 2018 for RCTs and prospective cohorts comparing clinical outcomes with statin vs non-statin use in patients with HF at different LVEF levels. We followed the guidelines of the 2…

0301 basic medicinemedicine.medical_specialtyStatinmedicine.drug_classEndocrinology Diabetes and MetabolismClinical Biochemistry610Heart failure030204 cardiovascular system & hematologyLower risklaw.invention03 medical and health sciences0302 clinical medicineEndocrinologyRandomized controlled trialHeart failure; Hospitalization; Meta-analysis; Mortality; StatinslawInternal medicineHumansMedicineCardiac and Cardiovascular SystemsProspective StudiesMortalitylcsh:RC620-627Kardiologibusiness.industryResearchBiochemistry (medical)Hazard ratioStatinsmedicine.diseaseConfidence interval3. Good healthHospitalizationlcsh:Nutritional diseases. Deficiency diseasesMeta-analysisTreatment Outcome030104 developmental biologyMeta-analysisHeart failureHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessCohort study
researchProduct

Effects of the Antidepressant Fluoxetine on the Somatostatin Interneurons in the Basolateral Amygdala

2018

Although the precise mechanism of action of antidepressant drugs remains elusive, the neuroplastic hypothesis has gained acceptance during the last two decades. Several studies have shown that treatment with antidepressants such as Fluoxetine is associated with enhanced plasticity in control animals, especially in regions such as the visual cortex, the hippocampus and the medial prefrontal cortex. More recently, the basolateral amygdala has been shown to be affected by Fluoxetine leading to a reopening of critical period-like plasticity in the fear and aggression circuits. One of the key elements triggering this type of brain plasticity are inhibitory networks, especially parvalbumin intern…

Male0301 basic medicineDendritic spinegenetic structuresInterneuronHippocampusMice TransgenicMice03 medical and health sciences0302 clinical medicineInterneuronsFluoxetineNeuroplasticitymedicineAnimalsPrefrontal cortexNeuronal PlasticitybiologyBasolateral Nuclear ComplexGeneral NeuroscienceAntidepressive Agents030104 developmental biologymedicine.anatomical_structureSomatostatinnervous systembiology.proteinSomatostatinNeuroscience030217 neurology & neurosurgeryParvalbuminBasolateral amygdalaNeuroscience
researchProduct

A case control study of statin and magnesium administration in patients after aneurysmal subarachnoid hemorrhage: incidence of delayed cerebral ische…

2008

To analyse the effect of the implementation of statin and magnesium treatment on delayed cerebral ischemia (DCI) and 14 day mortality in patients with subarachnoid hemorrhage (SAH).Retrospective, single-center, observational case control study. One hundred SAH patients received either simvastatin and magnesium, solely statin or no treatment.Eighteen percent (n=5) of patients receiving statin and magnesium treatment developed a DCI whereas 24% (n=5) in the statin group and 16% (n=8) in the control group had DCI. Dead by day 14 was registered in 18% (n=5) of patients in the statin and magnesium group, in 10% (n=2) in the statin group and in 27% (n=14) in the control group. None of the results…

MaleSimvastatinStatinSubarachnoid hemorrhagemedicine.drug_classIschemia610 Medicine & healthBrain Ischemia10180 Clinic for NeurosurgeryStatistical significancemedicineHumansMagnesiumcardiovascular diseasesRetrospective Studiesbusiness.industryIncidence (epidemiology)Anticholesteremic AgentsCase-control studynutritional and metabolic diseasesGeneral MedicineMiddle AgedSubarachnoid Hemorrhagemedicine.diseaseSurvival RateTreatment Outcome2728 Neurology (clinical)NeurologySimvastatinAnesthesiaCase-Control Studies2808 Neurologylipids (amino acids peptides and proteins)Observational studyFemaleNeurology (clinical)businessmedicine.drug
researchProduct

Muscle NAD+ depletion and Serpina3n as molecular determinants of murine cancer cachexia—the effects of blocking myostatin and activins

2020

Objective Cancer cachexia and muscle loss are associated with increased morbidity and mortality. In preclinical animal models, blocking activin receptor (ACVR) ligands has improved survival and prevented muscle wasting in cancer cachexia without an effect on tumour growth. However, the underlying mechanisms are poorly understood. This study aimed to identify cancer cachexia and soluble ACVR (sACVR) administration-evoked changes in muscle proteome. Methods Healthy and C26 tumour-bearing (TB) mice were treated with recombinant sACVR. The sACVR or PBS control were administered either prior to the tumour formation or by continued administration before and after tumour formation. Muscles were an…

MaleEXPRESSIONActivin receptor; APR; C26; Cancer cachexia; Nrk2; OXPHOSlcsh:Internal medicineCachexiaREVERSALActivin ReceptorsMETABOLISMactivin receptorOxidative PhosphorylationCell Line TumorAnimalsMuscle Skeletallcsh:RC31-1245aineenvaihduntaSerpinslihassolut318 Medical biotechnologyNrk2Cancer cachexiaMyostatinNADOXPHOSMUSCULAR-DYSTROPHYActivinsMitochondriaActivin receptorDisease Models AnimalMuscular AtrophyMICESIRTUINSOriginal ArticlesyöpätauditproteiinitC26lihassurkastumasairaudetAPRAcute-Phase Proteinscancer cachexia
researchProduct